Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2011 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (148)	2/6/2011 12:34:20 AM
From: technetium	Read Replies (2) \| Respond to of 400

How is CVR value calculated? How are shareholders paid? "The CVR is a tradable instrument, which promises a payout to shareholders over time based on the performance of Genzyme's experimental drug Lemtrada for multiple sclerosis. "It is not possible to pin down what the CVR will begin to trade at, but assuming it trades for $2 a share -- a reasonable estimate since many of Genzyme's shareholders are short-term investors who will want to sell immediately..." [url]http://www.reuters.com/article/2011/02/06/genzyme-sanofi-idUSN0512013320110206[/url] Disclaimer: I don't own any GENZ, but it's in my charity portfolio. P.S., How would Bulba factor in a CVR [contingent value right] when reallocating my picks? For simplicity, ignoring the CVR is fine by me, unless there is an immediate obvious way to place a value on it.